IFRS-based consolidated results supplement for the first quarter of the fiscal year ending March 2027. Net sales increased year over year; full-year guidance revised to 22,200 billion yen with YoY change indicated. Includes breakdown by key products and regions, currency effects, capital expenditure and depreciation, and adjustments to core earnings. Risks noted include market conditions, exchange rate fluctuations, and delays in new product launches.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4503","jir_company_name":"Astellas Pharma Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4503-20260805-02.pdf","jir_short_summary":"IFRS-based consolidated results supplement for the first quarter of the fiscal year ending March 2027. Net sales increased year over year; full-year guidance revised to 22,200 billion yen with YoY change indicated. Includes breakdown by key products and regions, currency effects, capital expenditure and depreciation, and adjustments to core earnings. Risks noted include market conditions, exchange rate fluctuations, and delays in new product launches.","jir_summary":"### Overview of results\nAstellas Pharma's IFRS-based Q1 FY2027 financial results supplement shows a substantial year-over-year increase in net sales, with notable growth in operating income and quarterly net income. Provides breakdowns by region and major product, currency effects, and adjustments to the core basis, with potential implications for revising full-year guidance. The supplement includes updates on new drug development and reference information; risks include market conditions, exchange rate fluctuations, and delays in new product launches.\n\n### Outlook and impact for investors\nFull-year guidance is indicated at 22,200 billion yen, with emphasis on growth rate YoY and contributions by segment. Currency effects are estimated to positively impact net sales by 60 billion yen and core operating income by 25.5 billion yen. Monitoring of new drug development progress and sales trends for key products is essential, with investors particularly focusing on regional sales composition, approval status of new drugs, and future capital allocation policy (including capital policy-related considerations).","jir_financial_highlights":"Net sales: 6,409 (YoY +1,351 (vs FY2025\/3, 26\/3 term: 5,058))\nOperating income: 1,845 (YoY +899 (vs 26\/3 term: 946\u21921,845))\nQuarterly profit: 1,418 (YoY +734 (vs 26\/3 term: 684\u21921,418))","jir_category":"","jir_hashtags":"#AstellasPharma, #financial_summary, #JapanEquities","jir_key_figures":"Net sales: 6,409 billion yen (1Q) YoY change: +1,351 billion yen\nOperating income: 1,845 billion yen (1Q) YoY change: +899 billion yen\nQuarterly profit: 1,418 billion yen (1Q) YoY change: +734 billion yen","jir_meta_title":"Astellas Pharma Q1 FY2027 Financial Results Supplement | Revenue and Profit Soar","jir_meta_description":"Astellas Pharma's Q1 FY2027 financial results supplement. Summary of IFRS-based net sales, operating income, and net income trends, regional\/product breakdown, currency effects, and key risk factors. Note on full-year guidance trends.","jir_og_title":"Astellas Pharma Q1 FY2027 Financial Results Supplement","jir_og_description":"Astellas Pharma Q1 results supplement. Summary of revenue and profit growth, regional\/product breakdown, currency effects, and outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6911,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95480","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n